Voices
Estela Rodriguez: Big Wave of Progress in HER2 Therapy – from Oral Targeted Agents to ADCs
Estela Rodriguez/doctors.umiamihealth.org and Eric Singhi/faculty.mdanderson.org

Estela Rodriguez: Big Wave of Progress in HER2 Therapy – from Oral Targeted Agents to ADCs

Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of Sylvester Comprehensive Cancer Center, shared a post on X:

“Dr Eric Singhi takes us on the big wave of progress in HER2 therapy from multiple oral targeted agents (zongertinib/sevabertinib/NVL330) to antibody–drug conjugates (T-DxD).

  • How to select the best drug based on efficacy and toxicity
  • How to sequence these agents.”

Estela Rodriguez: Big Wave of Progress in HER2 Therapy - from Oral Targeted Agents to ADCs

More posts featuring Estela Rodriguez.

cancer Eric Singhi Estela Rodriguez HER2 Therapy Lung cancer OncoDaily Oncology